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We identified Ras guanine-releasing protein 3 (RasGRP3) as a guanine exchange factor expressed in blood
vessels via an embryonic stem (ES) cell-based gene trap screen to identify novel vascular genes. RasGRP3 is
expressed in embryonic blood vessels, down-regulated in mature adult vessels, and reexpressed in newly formed
vessels during pregnancy and tumorigenesis. This expression pattern is consistent with an angiogenic function
for RasGRP3. Although a loss-of-function mutation in RasGRP3 did not affect viability, RasGRP3 was
up-regulated in response to vascular endothelial growth factor (VEGF) stimulation of human umbilical vein
endothelial cells, placing RasGRP3 regulation downstream of VEGF signaling. Phorbol esters mimic the
second messenger diacylglycerol (DAG) in activating both protein kinase C (PKC) and non-PKC phorbol ester
receptors such as RasGRP3. ES cell-derived wild-type blood vessels exposed to phorbol myristate acetate
(PMA) underwent extensive aberrant morphogenesis that resulted in the formation of large endothelial sheets
rather than properly branched vessels. This response to PMA was completely dependent on the presence of
RasGRP3, as mutant vessels were refractory to the treatment. Taken together, these findings show that
endothelial RasGRP3 is up-regulated in response to VEGF stimulation and that RasGRP3 functions as an
endothelial cell phorbol ester receptor in a pathway whose stimulation perturbs normal angiogenesis. This
suggests that RasGRP3 activity may exacerbate vascular complications in diseases characterized by excess
DAG, such as diabetes.
Blood vessels provide cells with the nutrients and oxygen
necessary for viability by forming a branched vascular network
that links to larger vessels, a process called angiogenesis. For
proper angiogenesis, endothelial cells must receive a number
of extracellular signals and then assemble these cues into a
coordinated biological response (for reviews, see references
16, 24, 30, 57, and 79). Vascular endothelial growth factor A
(VEGF-A) and its two high-affinity receptors, flk-1 (VEGF
receptor 2 [VEGFR-2]) and flt-1 (VEGFR-1), stimulate signal
transduction pathways that regulate endothelial cell prolifera-
tion, migration, survival, and permeability (for reviews, see
references 29, 64, and 72). VEGF-A is a secreted ligand ex-
pressed by nonendothelial cells developmentally and during
physiological and pathological angiogenesis in the adult. The
importance of VEGF-mediated signaling in vascular develop-
ment has been clearly demonstrated genetically, since muta-
tions in VEGF-A and both receptors lead to vascular pertur-
bations and embryonic death (11, 28, 31, 63). Moreover, recent
studies indicate that VEGF-A levels and perhaps spatial avail-
ability must also be regulated for blood vessels to form prop-
erly (15, 33, 50, 62).
Recently, the intracellular signaling pathways downstream
of VEGF-A in endothelial cells have been elucidated (for a
review, see reference 14). Signaling through Ras is one path-
way downstream of VEGF stimulation of flk-1 (18, 38, 48). Ras
is a key intracellular signaling hub that incorporates a number
of upstream signals and then coordinates these signals into
specific biological responses (for a review, see reference 65).
Biochemically, Ras is a small GTPase that functions as a GDP-
GTP-regulated switch. Stimulus-mediated activation of gua-
nine nucleotide exchange factors (GEFs) facilitates GDP-GTP
exchange and promotes the formation of active Ras-GTP (54),
whereas GTPase-activating proteins (GAPs) promote forma-
tion of inactive, GDP-bound Ras (6). VEGF stimulation of
endothelial cells increases the amount of activated Ras (18, 48,
66), and introduction of dominant negative Ras into endothe-
lial cells inhibits VEGF-induced endothelial cell DNA synthe-
sis, migration, and tube formation (48). Moreover, Ras signal-
ing is sufficient to promote an angiogenic phenotype in primary
endothelial cells in culture (49), suggesting that regulation of
endothelial Ras signaling is essential for blood vessel forma-
tion. However, the mechanism by which VEGF regulates Ras
and the precise role of Ras activation in mediating VEGF
function in endothelial cells are presently not well understood.
Genetic experiments in vivo are consistent with a role for
Ras in vascular development. Genetic ablation of Son of Sev-
enless (SOS) RasGEF, neurofibromatosis 1 (NF1) RasGAP, or
RasGAP results in cardiovascular defects (7, 36, 76). Partial
functional overlap exists within the ras family itself, as mice
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deficient for N-ras, H-ras, or both are normal (27, 74). K-ras
has a unique and required function, as mice deficient for K-ras
die progressively during development due to multiple defects,
including defects in the hematopoietic and cardiovascular sys-
tems (40, 45). Although expression of Ras and these Ras reg-
ulators is not restricted to blood vessels, targeted deletion of
NF1 RasGAP in endothelial cells leads to multiple cardiovas-
cular defects (34). This result indicates that NF1 is a required
gene product in endothelial cells during blood vessel develop-
ment and suggests that regulation of Ras signaling is important
in angiogenesis in vivo. However, the role of Ras activation in
blood vessel formation remains poorly understood.
We identified Ras guanine-releasing protein 3 (RasGRP3)
as an endothelial cell-expressed GEF in an embryonic stem
(ES) cell-based gene trap screen for genes expressed in blood
vessels (37, 67). RasGRP3 is one of four members of the
RasGRP family of RasGEFs that couple diacylglycerol (DAG)
signaling to Ras activation (12, 22, 41, 46, 47, 55, 56, 73, 78, 81).
While the different RasGRP proteins share similar mecha-
nisms of regulation, they exhibit distinct patterns of tissue
expression and specificity for Ras and Rap GTPases. We de-
termined that vascular expression of RasGRP3 was restricted
to sites of active blood vessel formation developmentally and in
the adult. The Rasgrp3 gene trap locus (Rasgrp3gt) is a loss-of-
function allele, yet homozygous Rasgrp3gt/gt mice and embryos
displayed no obvious vascular defects. However, wild-type ES
cell-derived vessels responded to the phorbol ester phorbol
myristate acetate (PMA), which mimics DAG activity, with
extensive aberrant morphogenesis. These changes required
RasGRP3 function, since Rasgrp3gt/gt vessels were completely
refractory to the phorbol ester-mediated effects. The aberrant
morphogenesis induced by phorbol ester in wild-type vessels
closely resembled the phenotype of vessels with up-regulated
VEGF signaling, and we showed that RasGRP3 expression is
up-regulated by VEGF stimulation of endothelial cells. Taken
together, these results show that RasGRP3 is a VEGF-respon-
sive vascular GEF that is essential for the endothelial response
to phorbol esters. RasGRP3 functions in a pathway that is
redundant developmentally, but its stimulation perturbs nor-
mal angiogenesis, suggesting that it may exacerbate DAG-
mediated vascular phenotypes in diseases such as diabetes.
MATERIALS AND METHODS
Generation of Rasgrp3/gt ES cells. ES cells were maintained and differenti-
ated as previously reported (4, 42, 43). ES cells with a gene trap vector in the
Rasgrp3 locus (Rasgrp3/gt) were identified by analysis of -galactosidase (-Gal)
expression upon differentiation as previously described (37, 67). Briefly, the
PT1-ATG vector, which contains a promoterless lacZ gene with its own start
codon, was introduced into ES cells by electroporation, and selection was per-
formed with G418. Drug-resistant colonies were picked, expanded, differenti-
ated, and analyzed for -Gal expression in blood vessels.
-Gal detection. Differentiated ES cell cultures, embryos, and adult tissues
were processed for -Gal detection as previously described (42). Briefly, ES cell
cultures were differentiated to day 6 to 8 and then fixed in glutaraldehyde fixative
(0.2% glutaraldehyde, 5 mM EGTA [pH 7.3], 2 mM MgCl2 in 0.1 M phosphate
buffer [pH 7.3]) for 5 min at room temperature. After three washes with phos-
phate buffer, cultures were incubated overnight at 37°C in 5-bromo-4-chloro-3-
indolyl-ā-D-galactopyranoside (X-Gal; Sigma) staining solution (0.625 mg of
X-Gal/ml, 5 mM potassium ferrocyanide and 5 mM potassium ferricyanide in ES
cell wash buffer). ES cell wash buffer consisted of 2 mM MgCl2 and 0.02% NP-40
in 0.1 M sodium phosphate buffer (pH 7.3). After incubation, cultures were
rinsed and stored in wash buffer at 4°C.
Embryos and adult tissues were rinsed in 1 phosphate-buffered saline (PBS)
and fixed in either glutaraldehyde fixative or 4% paraformaldehyde (PFA)–PBS
for 20 min at room temperature. After two 10-min washes in embryo wash buffer
(0.1 M phosphate buffer [pH 7.3], 0.1% sodium deoxycholate, 0.02% NP-40,
0.05% bovine serum albumin [Sigma]), tissues were incubated overnight at 37°C
in X-Gal staining solution (wash buffer containing 1 mg of X-Gal/ml [Sigma], 5
mM ferrocyanide, and 5 mM ferricyanide). Tissues were then postfixed in the
appropriate fixative and stored at 4°C until embedded. Adult tissues were fre-
quently dissected into smaller pieces prior to fixation for better penetration.
RACE cloning. Rapid amplification of cDNA ends (RACE) cloning was done
as previously described (67). Briefly, RNA was prepared from differentiated ES
cell cultures with Trizol (Roche Applied Sciences, Indianapolis, Ind.) per the
manufacturer’s protocol. RACE cloning was performed with a 5 RACE kit
(GIBCO/BRL, Grand Island, N.Y.) according to the manufacturer’s instructions.
RACE products were subcloned into the pCRII vector (Invitrogen, Carlsbad,
Calif.).
Nucleic acid isolation and analysis. For Southern blot analysis, genomic DNA
was digested with EcoRI, separated on a 0.8% agarose gel, and transferred to a
nylon membrane. Hybridization was performed with a RasGRP3-specific cDNA
probe generated by RACE cloning. This probe encompassed exons 2 to 4 of
RasGRP3 and part of exon 1. Primer sequences for PCR genotyping were 5
ATC TGG AGC CCA TTG AGT TG 3 and 5 CAG GCC AGA ACC AAG
AGG TC 3, flanking exon 3 of RasGRP3, and 5 TGC CCT TTC TCC TCC
ATG AC 3 and 5 GCG GGC CTC TTC GCT ATT AC 3, which are specific
for the gene trap (see Fig. 2A).
Total RNA was isolated from cells or tissues with Trizol Reagent, per the
manufacturer’s protocol, for Northern blot analysis. RNA was separated on a
1.2% formaldehyde–agarose gel and transferred to nitrocellulose. The mem-
brane was hybridized in Quickhyb hybridization buffer (Stratagene, La Jolla,
Calif.) with [32P]dCTP-labeled cDNAs and then exposed to film. All radioactive
probes were generated by random priming with the Prime-It RmT Random
Primer labeling kit (Stratagene). Template for the mouse RasGRP3 Northern
probe was generated using the primers 5 GCT CGG GAA AGC GGC AAC AC
3 and 5 ATT GGC GGT CTG GCT TTG G 3, corresponding to nucleotides
344 to 1575 of mouse RasGRP3. Human RasGRP3 probe was generated using
a 772-bp HindIII fragment from a human RasGRP3 cDNA clone, KIAA0846
(51). This probe corresponds to nucleotides 2643 to 3415 of KIAA0846. The
platelet endothelial cell adhesion molecule (PECAM) probe was generated from
a 660-bp reverse transcriptase PCR (RT-PCR) product that corresponds to
nucleotides 1244 to 1904 of PECAM.
Generation, maintenance, and genotyping of mice. Chimeric mice were pro-
duced from Rasgrp3/gt ES cells by injection of ES cells into the blastocoel cavity
of mouse blastocysts (32). The Rasgrp3gt strain was established using three inde-
pendent chimeras that demonstrated germ line transmission when bred to wild-
type CD1 mice. For timed pregnancies, day 0.5 of gestation (E0.5) was noon of
the day of vaginal plug observation. Genotyping was performed using DNA
isolated from tail biopsies or embryonic yolk sac by Southern blotting or PCR
analysis. MMTV-PyVT mice (the gift of W. Muller and T. Van Dyke) were
crossed to Rasgrp3gt mice through two rounds of matings to obtain MMTV-
PyVT;Rasgrp3/gt and MMTV-PyVT;Rasgrp3gt/gt mice.
In situ hybridization. In situ hybridization on whole-mount embryos was
performed by a modified protocol (61). The template for the RasGRP3 probe
was the same template used for mouse Northern blot analysis. Briefly, mid-
gestation embryos were isolated and fixed in 4% PFA–PBS overnight. Embryos
were then dehydrated in a methanol–PBS series, followed by rehydration in a
methanol–PBT (PBS with 0.1% Tween) series. Embryos were bleached in 6%
H2O2 for 1 h, treated with 10 g of proteinase K/ml in PBT for 15 min, and then
washed with fresh 2 mg of glycine in PBT/ml. Refixation was performed using
0.2% glutaraldehyde–4% PFA in PBT for 20 min. Embryos were incubated in
prehybridization solution (50% formamide, 5 SSC [1 SSC is 0.15 M NaCl
plus 0.015 M sodium citrate] [pH 4.5], 0.1% Tween 20, and 0.05 mg of heparin/
ml) for 1 h at 70°C prior to adding heat-shocked digoxigenin-labeled probe (1
g/ml). Hybridization was performed overnight at 70°C.
Following hybridization, embryos were washed according to protocol and then
incubated with 100 g/ml RNase A for 30 min at 37°C. Blocking was performed
using 10% lamb serum in Tris-buffered saline plus 0.1% Tween 20 (TBST) for
2.5 h at room temperature, and embryos were incubated with an alkaline phos-
phatase-conjugated anti-digoxigenin antibody (Boehringer Mannheim, India-
napolis, Ind.) at a 1:2,000 dilution overnight at 4°C. After antibody incubation,
embryos were washed in TBST, and detection was with 50 mg of nitroblue
toluene/ml and 30 mg of 5-bromo-4-chloro-3-indolyl phosphate (BCIP)/ml
(both from Promega, Milwaukee, Wis.) in 100 mM NaCl, 100 mM Tris-HCl (pH
9.5), 50 mM MgCl2, 0.1% Tween 20, and 2 mM levamisole. When detection was
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complete, embryos were washed in PBT (pH 5.5) and then postfixed in 4% PFA.
Embryos were stored in PBS at 4°C.
RNA in situ hybridization of differentiated ES cell cultures was performed as
previously reported (5) and as described above for embryos except for the
following: day 8 cultures were fixed in 4% PFA for 1 h and dehydrated through
a methanol-PBS series. Wells were rehydrated and then incubated in 6% H2O2
in PBT for 30 min, in proteinase K (3 g/ml in PBT) for 10 min, and then in fresh
glycine (2 mg/ml in PBT) for 4 min. Following the PBT washes, wells were refixed
in 0.2% glutaraldehyde and 4% PFA in PBT for 8 min. Wells were hybridized as
above except that an initial 3-h incubation was performed at 80°C prior to
addition of probe. RNase treatment, blocking incubation, antibody reaction, and
substrate development were all as previously described.
Antibody staining. Antibody staining of ES cell cultures was as previously
described (5, 42). Rat anti-mouse PECAM was used at a 1:1,000 dilution (Mec
13.3; BD Pharmingen, San Diego, Calif.), and donkey anti-rat tetramethyl-rho-
damine isothiocyanate (Jackson Immunoresearch, West Grove, Pa.) was used at
a 1:200 dilution. Cultures were stored at 4°C in PBS. Antibody staining of
mid-gestation embryos was also as previously described (1, 2). Embryos were
incubated with rat anti-mouse PECAM (Mec 13.3; BD Pharmingen) at a 1:200
dilution, followed by incubation with horseradish peroxidase-conjugated goat
anti-rat secondary antibody (Pierce, Rockford, Ill.) at a 1:200 dilution. Detection
was with 0.5 mg of 3,3-diaminobenzidine tetrahydrochloride (Sigma)/ml, 3 mg
of nickel sulfate/ml, and 0.03% hydrogen peroxide in PBS.
HUVEC stimulation. Human umbilical vein endothelial cells (HUVECs) were
purchased from Cambrex Bio Science Walkersville, Inc. (Walkersville, Md.) and
maintained in endothelial growth medium 2 supplemented with the CC-4176
bullet kit per the manufacturer’s protocol. HUVECs were utilized between
passages 4 and 8. For RasGRP3 regulation experiments, HUVECs were grown
to near-confluency, then serum starved overnight in M199 supplemented with
2% fetal bovine serum. HUVECs were then stimulated with various concentra-
tions of VEGF or basic fibroblast growth factor (bFGF) for 24 h, and isolated
RNA was analyzed on Northern blots. Recombinant human VEGF164 (R&D
Systems) was used at 5 to 60 ng/ml, and recombinant human bFGF (Sigma) was
used at 5 to 80 ng/ml.
Production of Rasgrp3gt/gt ES cells. Rasgrp3/gt ES cells were seeded at 5  104
cells per 10-cm plate in ES cell medium (4, 43), and 1 day later, 640 g of
G418/ml was added to the medium. After 10 to 14 days of G418 selection,
colonies were picked, expanded, and screened for homozygosity at the Rasgrp3
locus by PCR and Southern blot analysis. Three different Rasgrp3gt/gt ES cell
clones were characterized.
PMA treatment of differentiating ES cell cultures. PMA (Calbiochem, San
Diego, Calif.) was resuspended in dimethyl sulfoxide at 10 mM. PMA (10 to
1,000 nM) was added to differentiating ES cell cultures starting on day 5 of
differentiation. Fresh PMA was then added daily. At day 8, cultures were fixed
and processed for antibody staining as previously described.
RESULTS
Identification of a gene trap insertion in the Rasgrp3 locus.
We carried out a gene trap screen in ES cells to identify novel
genes expressed in developing blood vessels or blood cells (37,
67). The approach was to induce random insertion into ES
cells of a vector that both lacked a promoter/enhancer and
contained a splice acceptor site. Thus, expression of the re-
porter should be facilitated by insertion into an intron, and the
expression pattern is predicted to reflect the expression pattern
of the insertion locus. ES cells can be induced to undergo a
programmed differentiation in vitro that recapitulates devel-
opmental processes and results in the formation of multiple
tissues, including primitive blood vessels (4). The combination
of gene trap insertion and ES cell differentiation to primitive
vessels is a powerful approach for the identification of new
genes and/or genes not previously associated with blood vessel
formation.
One such gene trap ES cell line selectively expressed the
-Gal reporter gene in developing ES cell-derived blood ves-
sels (Fig. 1A). Initial RACE cloning combined with analysis of
expressed sequence tag databases and the mouse genome se-
quence indicated that the gene trap insertion occurred at the 5
end of a gene encoding the small GTPase activator RasGRP3
(Fig. 2A). To confirm that the insertion occurred in this locus,
we performed Southern blot analysis of DNA from ES cells
that were wild type (Rasgrp3/), heterozygous (Rasgrp3/gt),
or homozygous (Rasgrp3gt/gt) for the gene trap insertion (Fig.
2B). A band shift was detected in Rasgrp3/gt and Rasgrp3gt/gt
DNA with a RasGRP3 probe, confirming that the gene trap
insertion did indeed occur in the Rasgrp3 locus.
Further analysis of the genomic DNA showed three hybrid-
izing EcoRI fragments in wild-type DNA, but only two such
bands in Rasgrp3gt/gt DNA (Fig. 2B). Although other possibil-
ities exist, the simplest explanation for this result is that the
gene trap insertion deleted one of the Rasgrp3 exons. To test
this hypothesis, we performed PCR experiments to assay for
the presence of exons 2, 3, and 4 in genomic DNA (Fig. 2C).
All three primer sets amplified fragments from wild-type and
heterozygous DNA, and exon 2 and 4 primer sets amplified
fragments from Rasgrp3gt/gt DNA. However, a PCR product
corresponding to exon 3 was not amplified from Rasgrp3gt/gt
DNA, suggesting that exon 3 was deleted by the gene trap
insertion (Fig. 2A). This result is consistent with the fragment
sizes detected by Southern blot analysis and suggests that the
Rasgrp3gt locus is a null allele, since exon 3 contains the AUG
start codon of RasGRP3.
Analysis of the mouse genome sequence predicted that the
mouse RasGRP3 transcript was approximately 4.2 kb and con-
tained 18 exons. We cloned the predicted open reading frame
of this transcript by RT-PCR from the mouse endothelial cell
line Py-4-1 (21), and sequenced the transcript (Fig. 3A). The
mouse RasGRP3 protein is predicted to be 691 amino acids,
with four conserved domains shared by all RasGRP proteins: a
REM (Ras exchange motif) domain, a CDC25 homology do-
main, a pair of atypical EF hands, and a regulatory C1 domain
(Fig. 3B). The RasGRPs activate Ras and other small GTPases
via the CDC25 homology catalytic domain, and they are acti-
vated in turn by the formation of DAG, which resides in the
membrane. The C1 domain interacts with DAG, causing re-
cruitment of RasGRP to the plasma membrane, where mem-
brane-bound Ras is stimulated (Fig. 3C) (for a review, see
reference 17). Phospholipase C- (PLC-) generates DAG by
cleaving PIP2, and PLC- is downstream of receptor tyrosine
kinases such as the VEGF receptor (69). Mouse RasGRP3
FIG. 1. RasGRP3 is expressed in ES-cell derived blood vessels.
(A) ES cells with a lacZ-containing gene trap integration in the Ras-
grp3 locus (Rasgrp3/gt) were differentiated to day 8 (day 8 ES cell
cultures) and stained for -Gal. -Gal expression was detected in ES
cell-derived blood vessels. (B) Wild-type (Rasgrp3/) day 8 ES cell
cultures were hybridized with an in situ hybridization probe specific for
RasGRP3. Arrows point to several blood vessels that reacted with the
probe.
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shares extensive nucleotide and protein homology to human
RasGRP3 and to the other three RasGRP family members
from both species (data not shown).
The expression of RasGRP3 in ES cell-derived blood vessels
suggested that this activator might be involved in angiogenesis.
Three criteria were considered important in assigning Ras-
GRP3 a role in vascular processes: (i) vascular expression
during embryonic development, (ii) endothelial cell expression
during neoangiogenesis in the adult, and (iii) altered blood
vessel formation upon perturbation of RasGRP3 function.
These criteria were assessed with molecular, genetic, and phar-
macological tools.
RasGRP3 is expressed in blood vessels during mouse devel-
opment. Because Ras is a critical transducer of numerous sig-
nals important for cell proliferation and differentiation, we
asked if RasGRP3 was expressed developmentally. To do this,
we generated Rasgrp3/gt mice from Rasgrp3/gt ES cells using
standard techniques, and analyzed expression of RasGRP3 via
the -Gal reporter gene. We focused on a developmental win-
dow from E7.5 to E10.5 because this is when vascular devel-
opment is most prominent. During development, -Gal ex-
pression from the Rasgrp3 locus was predominately found in
blood vessels. In E9.5 and E10.5 embryos, -Gal was strongly
expressed in the developing intersomitic vessels and the dorsal
aorta (Fig. 4A and B). The majority of head vessels and small
vessels along the sides of the embryo also faintly expressed
-Gal. -Gal expression in developing vessels was not uniform
at a given stage, suggesting that RasGRP3 expression is mod-
ulated developmentally. -Gal from the Rasgrp3 locus was also
expressed in a limited number of nonvascular embryonic cells
such as the pericardium and the myotome of the somite (Fig.
4A and B and data not shown). Examination of transverse
FIG. 2. The gene trap construct integrated into the Rasgrp3 locus. (A) Schematic of the mouse Rasgrp3 locus. The locus is approximately 63
kb and consists of 18 exons. The region encompassing exons 2 to 7 is enlarged to show the restriction fragments analyzed by Southern blot analysis.
E, EcoRI sites. Arrows denote PCR primers for genotyping Rasgrp3 mice. (B) Southern blot analysis of EcoRI-digested genomic DNA from
Rasgrp3/(lane 1), Rasgrp3/gt (lane 2), and Rasgrp3gt/gt (lane 3) mice. The blot was hybridized with a cDNA probe consisting of exons 2 to 4.
Arrows denote hybridizing fragments in Rasgrp3/ DNA. Arrowheads denote the hybridizing fragments inRasgrp3gt/gt DNA. (C) Genomic PCR
with primers specific for exons 2 to 4 and the gene trap. Rasgrp3/(lane 1), Rasgrp3/gt (lane 2), and Rasgrp3gt/gt (lane 3) are shown.
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sections at E9.5 revealed -Gal expression in the dorsal aortae,
cardinal veins, and the perineural vascular plexus that sur-
rounds the developing spinal cord (Fig. 4C).
To determine if -Gal expression from the Rasgrp3 locus
faithfully recapitulated expression of the endogenous gene, we
utilized whole-mount in situ hybridization with a probe for
RasGRP3 that did not recognize other family members. Ras-
GRP3 RNA was detected in ES cell-derived vessels, the dorsal
aorta, and intersomitic vessels and faintly in the small vessels of
the head (Fig. 1B and 4D). This expression pattern closely
resembles the whole-mount -Gal expression pattern, confirm-
ing that the -Gal reporter recapitulates vascular expression of
endogenous RasGRP3.
RasGRP3 expression is modulated during angiogenesis and
by VEGF. Although RasGRP3 was expressed in blood vessels
of the developing embryo, the majority of vessels in the adult
mouse lacked RasGRP3 -Gal expression (Fig. 5A and B).
Additionally, there was only rare expression of RasGRP3
-Gal in adult nonvascular cells in organs such as the brain and
spleen (data not shown). Since RasGRP3 was expressed in
FIG. 3. Cloning and analysis of the RasGRP3 cDNA. (A) Full-length RasGRP3 was cloned from the mouse endothelial cell line Py-4-1 by
RT-PCR and sequenced. Underlined sequences represent conserved domains. (B) Schematic of RasGRP3 protein. REM, RasGEF N-terminal
domain; CDC25, catalytic RasGEF domain; EF, atypical EF hand domain; C1, PKC region 1 domain that binds DAG. (C) Model of RasGRP3
activation and signaling. Upon ligand-receptor engagement, PLC- is activated, which leads to the production of DAG from PIP2. DAG is localized
to the plasma membrane. C1 domain binding of DAG recruits RasGRP3 to the membrane where Ras activation occurs.
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embryonic vessels undergoing angiogenesis, we asked whether
vascular RasGRP3 expression is up-regulated during adult an-
giogenesis. During pregnancy, vessels of the female reproduc-
tive tract undergo extensive expansion to provide nutrients and
oxygen to the developing fetus. RasGRP3 -Gal was expressed
in maternal vessels of the decidua that surrounds the murine
embryo, suggesting that RasGRP3 is reexpressed in these adult
angiogenic vessels (Fig. 5C).
As tumors proliferate, they recruit host-derived blood ves-
sels via angiogenesis. To address regulation of RasGRP3 in
tumor vessels, we first took advantage of a Rasgrp3gt/gt mouse
that developed spontaneous sarcomas. We found that Ras-
GRP3 -Gal was reexpressed in these tumor blood vessels
(Fig. 5D). To further extend this analysis, we obtained MMTV-
PyVT transgenic mice, and bred this transgene into the
Rasgrp3gt background. MMTV-PyVT mice rapidly develop
mammary tumors as a consequence of PyVT oncogene expres-
sion in the mammary glands, and the resulting tumors are
highly angiogenic (35). Analysis of MMTV-PyVT;Rasgrp3gt/gt
mice revealed that RasGRP3 -Gal was also reexpressed in the
vessels of these tumors (Fig. 5E). Taken together, these results
indicate that vascular RasGRP3 expression is up-regulated
during both normal and pathological angiogenesis.
Although most adult vessels did not express RasGRP3, Ras-
GRP3 was expressed constitutively in the kidney glomerulus
(Fig. 6A and B) as was previously reported (78). VEGF ex-
FIG. 4. RasGRP3 is expressed in blood vessels developmentally. (A and B) Embryos at E9.5 (A) and E10.5 (B) with lacZ inserted into the
Rasgrp3 locus (Rasgrp3/gt) were stained for -Gal. -Gal expression was detected in the dorsal aorta, the intersomitic vessels, and many of the
smaller vessels throughout the embryo. The black arrow points to RasGRP3 -Gal expression in the dorsal aorta, black arrowheads indicate
expression in the intersomitic vessels, the white arrowhead indicates somitic myotome expression, and the white arrow indicates expression in the
pericardium. (C) Transverse section of an E9.5 embryo stained for RasGRP3 -Gal. NT, neural tube; PNVP, perineural vascular plexus; CV,
cardinal veins; DA, dorsal aortae. (D) Whole-mount in situ hybridization of Rasgrp3/ wild-type E9.5 embryo for RasGRP3. RasGRP3 mRNA
was detected in the dorsal aorta, intersomitic vessels, and several smaller vessels throughout the embryo. The arrow designates expression in the
dorsal aorta, whereas arrowheads indicate expression in the intersomitic vessels.
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pression is also maintained in adult kidney glomeruli (9, 25);
the VEGF receptor, flk-1 (VEGFR-2), is also expressed at this
site (Fig. 6C and D) (58), indicating that VEGF signaling is
intact in the glomerulus. Thus, VEGF expression is associated
with neoangiogenesis in the embryo and the adult, and it is
maintained in the glomerulus of the kidney, all sites of Ras-
GRP3 expression. This coincidence suggested that VEGF sig-
naling through flk-1 may induce RasGRP3 expression in vivo.
We tested this hypothesis by treating primary endothelial
cells in culture (HUVECs) with increasing concentrations of
recombinant VEGF. RasGRP3 RNA was barely detectable in
serum-starved HUVECs by Northern blot analysis; however,
VEGF stimulation resulted in up-regulation of RasGRP3 tran-
scription in a dose-dependent manner, indicating that Rasgrp3
is a VEGF-responsive gene (Fig. 7A). This effect was not
universal to growth factor stimulation, as HUVEC stimulated
with another angiogenic growth factor, bFGF, did not show
increased RasGRP3 RNA levels (Fig. 7B).
RasGRP3 is a phorbol ester receptor that functions in en-
dothelial cells. The RasGRP3 gene trap insertion most likely
deleted exon 3 of Rasgrp3, which contains the predicted start
codon for the RasGRP3 protein, so the gene trap insertion is
likely to have resulted in a null mutation (Fig. 2A). To further
investigate this possibility, we analyzed total RNA isolated
from Rasgrp3/, Rasgrp3/gt, and Rasgrp3gt/gt E9.5 embryos
and day 8 ES cell cultures for RasGRP3 mRNA by Northern
blot analysis (Fig. 7C). In all cases, RasGRP3 mRNA was
readily detectable in Rasgrp3/ and Rasgrp3/gt samples; how-
ever, no RasGRP3 transcript could be detected in Rasgrp3gt/gt
samples. This result strongly indicates that the gene trap in-
sertion resulted in a null mutation in Rasgrp3, although we
cannot exclude the formal possibility that it is a severe hypo-
FIG. 5. RasGRP3 expression is up-regulated during normal and pathological adult angiogenesis. (A) Brain section from a Rasgrp3/gt mouse
stained for -Gal. Note the absence of -Gal staining in the blood vessels. The insert shows a vessel (black arrow) at higher magnification that does
not express -Gal. (B) Equivalent brain section from a flt-1/ mouse with lacZ inserted in the flt-1 locus. Note the -Gal expression in the brain
blood vessels. (C) Rasgrp3gt/gt decidua stained for -Gal. Note expression of -Gal in decidual vessels. (D) Spontaneous tumor from a Rasgrp3gt/gt
mouse, stained for -Gal. Note expression of -Gal in tumor vessels. (E) Section of a mammary tumor from a MMTV-PyVT;Rasgrp3gt/gt mouse
stained for -Gal. Note the expression of -Gal in tumor vessels. The insert shows a -Gal-positive vessel at a higher magnification. The arrow
points to the lumenized vessel.
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morphic mutation. Moreover, we were unable to detect expres-
sion of RasGRP3 in Rasgrp3gt/gt embryos and day 8 ES cell
cultures by in situ hybridization (data not shown), further sup-
porting the conclusion that functional RasGRP3 RNA is not
made from the Rasgrp3gt locus.
To determine if loss of RasGRP3 affected development, we
intercrossed Rasgrp3/gt mice and analyzed the progeny.
Rasgrp3gt/gt mice were born at the expected Mendelian ratio,
and the life spans of these mice were comparable to those of
littermate controls, indicating that RasGRP3 is not required
for development or viability (data not shown). Furthermore,
no differences in reproductive ability were observed. The blood
vessels of Rasgp3gt/gt mice also appeared normal, as no hem-
orrhage or morphological defects were detected (data not
shown). Because RasGRP3 expression is regulated develop-
mentally, we asked whether Rasgrp3gt/gt embryos had a subtle
vascular phenotype that was rescued prior to birth. To address
this issue, we isolated mid-gestation embryos from Rasgrp3/gt
intercrosses and stained them with the vascular marker PE-
CAM. Compared to blood vessels of littermate controls, the
blood vessels of Rasgrp3gt/gt embryos appeared normal (Fig. 8A
to C). Consistent with these in vivo results, the vasculature of
differentiated Rasgrp3gt/gt ES cell cultures also appeared nor-
mal (Fig. 8D to F). The Rasgrp3gt/gt vessels were the proper
thickness and branched appropriately, with normal variation in
those parameters as seen in wild-type controls.
Since RasGRP3 was up-regulated during tumor angiogene-
sis, the consequences of RasGRP3 deficiency during tumor
development were investigated. Compared to littermate con-
trols, the kinetics and frequency of mammary tumor develop-
ment in MMTV-PyVT;Rasgrp3gt/gt mice were not affected (data
not shown). We also examined the kidneys of Rasgrp3gt/gt mice
by histology and found no obvious lesions or abnormalities
(data not shown). Taken together, these results indicate that
RasGRP3 deficiency does not result in an obvious vascular
phenotype at the stages and sites analyzed.
RasGRP3 localization and activity is regulated by DAG, and
this interaction is mimicked by the phorbol ester PMA. Thus,
PMA is predicted to increase RasGRP3 activity and Ras acti-
vation (47). Normally, ES cell-derived blood vessels form a
vascular plexus consisting of thin vessels that branch at regular
intervals (Fig. 9A to C); however, wild-type ES cell-derived
vessels treated with PMA underwent extensive alterations and
formed large sheets with little branching (Fig. 9D). Formation
of these endothelial sheets required RasGRP3 activity, since
RasGRP3gt/gt cultures treated with PMA did not form vascular
sheets, but instead had morphologically normal vessels (Fig.
9F). This was true of three independent isolates of homozy-
gous Rasgrp3gt/gt ES cells. RasGRP3/gt cultures treated with
PMA displayed an intermediate phenotype (Fig. 9E), suggest-
ing a dose response to the PMA-induced morphological
changes mediated by RasGRP3. PMA-induced morphological
changes in vessels occurred over a range of PMA concentra-
tions from 10 to 1,000 nM (data not shown).
The alteration of vessels observed following PMA addition
to wild-type ES cell cultures closely resembles the vascular
phenotype resulting from genetic ablation of the VEGF recep-
tor, flt-1 (Fig. 9G), which up-regulates VEGF signaling. Be-
cause the PMA-induced vascular changes required RasGRP3
activity, we asked whether RasGRP3 was up-regulated in the
flt-1/ background. Northern blot analysis revealed that,
when normalized to the amount of vasculature, RasGRP3
FIG. 6. RasGRP3 and flk-1 are both expressed in the glomerulus of the kidney. Kidneys from Rasgrp3/gt mice and flk-1/ mice with lacZ
inserted into the flk-1 locus were dissected and stained for -Gal. (A and C) Whole-mount view of -Gal expression in Rasgrp3/gt (A) and flk-1/
(C) kidneys. Note the peripheral, punctate expression of -Gal in both backgrounds. (B and D) Kidney sections from Rasgrp3/gt (B) and flk-1/
(D) mice stained for -Gal. Note that the -Gal reporter is expressed in the glomerulus in both genetic backgrounds.
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RNA levels were increased 1.5-fold in flt-1/ cultures (Fig.
10). Taken together, these results suggest that increased Ras-
GRP3 activity may contribute to the aberrant morphology of
flt-1/ vessels.
DISCUSSION
This study identifies RasGRP3 as a GEF expressed in the
vasculature. Its expression is associated with developing vessels
in the embryo and in the adult, suggesting that Ras activation
through RasGRP3 is utilized for angiogenesis. Indeed, Ras-
GRP3 expression is directly regulated by VEGF signaling, and
the VEGF pathway is critical for angiogenesis. Moreover, Ras-
GRP3 is required to mediate the aberrant endothelial mor-
phogenesis that results from PMA exposure, a treatment that
phenocopies aspects of up-regulated VEGF signaling. Taken
together, our results indicate that RasGRP3 is a phorbol ester
receptor that functions in endothelial cells, where it transduces
signals that modulate angiogenic activity.
Endothelial RasGRP3 expression is regulated by angiogen-
esis and VEGF. RasGRP3 belongs to a GEF subfamily of four
highly related proteins that contain a C1 domain. This domain
binds DAG, a membrane-localized second messenger, and
brings the GEF into close proximity to membrane-localized
GTPases to effect its activation function. Mouse RasGRP3
shares extensive sequence homology with human RasGRP3
and with the other family members (78). RasGRP family mem-
bers, including RasGRP3, are expressed in hematopoietic
cells: RasGRP1 is expressed in T cells, RasGRP4 is expressed
in myeloid cells, and RasGRP3 is expressed in B cells (19, 23,
53, 56, 81). RasGRP2 has a more ubiquitous hematopoietic
expression profile (G. Reuther and C. Der, personal commu-
nication), and RasGRP1 to RasGRP3 are expressed in some
nonhematopoietic tissues such as brain and kidney (78). Given
that endothelial cells share expression of numerous genes with
hematopoietic cells, it is not surprising that we identified mu-
rine RasGRP3 in our gene trap screen to uncover novel vas-
cular genes. B cells do not mature from ES cells in our differ-
entiation protocol, and they are not present in mid-gestation
embryos, so we did not score B-cell expression of RasGRP3.
We did score expression of RasGRP3 using the -Gal reporter
readout in embryonic tissues such as the somitic myotome and
the pericardium and in rare nonendothelial adult cells. How-
ever, RasGRP3 expression was most consistently found in
blood vessels undergoing angiogenesis in both embryos and
adults, suggesting that Ras activation through RasGRP3 ac-
companies angiogenesis.
The up-regulation of RasGRP3 expression during angiogen-
esis suggested that angiogenic signaling may regulate expres-
sion of this locus. VEGF signaling is a prominent feature of
angiogenesis throughout life, and RasGRP3 expression is up-
regulated upon VEGF stimulation of primary endothelial cells.
VEGF-dependent up-regulation of RasGRP3 was also docu-
mented in a microarray analysis (80). Although VEGF signal-
ing is dramatically down-regulated in quiescent vessels, the
pathway remains active in the glomerulus of the kidney, where
it is required to establish and maintain endothelial fenestra-
tions for filtration (25, 26, 60). Likewise, RasGRP3 expression
is maintained at this site, suggesting that Ras activation via
RasGRP3 is involved in this process. RasGRP3 expression is
also up-regulated in the maternal vessels of the decidua and in
vessels that form in response to tumor angiogenic signals.
These findings are consistent with a model in which RasGRP3
expression is downstream of VEGF signaling and VEGF stim-
ulation increases the amount of RasGRP3 RNA in HUVECs.
It will be interesting to determine the intracellular pathways
downstream of VEGF that mediate up-regulation of RasGRP3
expression.
RasGRP3 is not necessary for angiogenesis but mediates the
endothelial response to phorbol esters. Numerous studies im-
plicate Ras signaling in endothelial function and vascular de-
velopment (34, 36, 76). Generation of a Rasgrp3 loss-of-func-
tion allele allowed us to assess the effects of RasGRP3
deficiency in developing vessels. Homozygous Rasgrp3gt/gt ES
cell-derived vessels formed normally, and Rasgrp3gt/gt mutant
embryos and mice had no obvious phenotype. RasGRP2 is
required for proper platelet aggregation (13) and RasGRP1 is
required for T-cell maturation in vivo (19), but we did not
observe similar defects in Rasgrp3gt/gt endothelial cells. This is
not surprising, because redundancy for RasGRP3 function is
predicted. It is possible that expression of other RasGRPs
and/or other RasGEFs provides a compensatory activating
FIG. 7. Rasgrp3 is a VEGF-responsive gene and a loss-of-function
mutation. (A and B) HUVECs were incubated with increasing con-
centrations of VEGF (5 to 60 ng/ml) (A) or bFGF (5 to 80 ng/ml) (B).
After 24 h, RNA was collected and subjected to Northern blot analysis.
(C) RasGRP3 Northern blot analysis was performed on RNA isolated
from Rasgrp3/, Rasgrp3/gt, and Rasgrp3gt/gt E9.5 embryos and day 8
ES cell cultures.
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function. We detected RasGRP2 but not RasGRP1 or Ras-
GRP4 in a murine endothelial cell line by RT-PCR analysis,
suggesting that RasGRP2 function may compensate for loss of
RasGRP3 (D. Roberts and V. Bautch, unpublished results).
However, RasGRP2 is a Rap1 activator and not a Ras activa-
tor, whereas RasGRP3 is an activator of Ras and Rap1. There-
fore, other RasGEFs may also compensate for the loss of
RasGRP3 regulation of Ras. There are multiple RasGEFs
expressed in most cells, and other GEFs such as the Drosophila
melanogaster RhoGEF GEF64C do not exhibit a loss-of-func-
FIG. 8. Rasgrp3gt/gt embryos and ES cell cultures do not have an obvious vascular phenotype. Rasgrp3/, Rasgrp3/gt, and Rasgrp3gt/gt E9.5
embryos and day 8 ES cell cultures were incubated with anti-PECAM antibody and reacted with 3,3-diaminobenzidine tetrahydrochloride (A to
C) or an immunofluorescent secondary antibody (D to F). Rasgrp3/ (A and D), Rasgrp3/gt (B and E), and Rasgrp3gt/gt (C and F) embryos or
cultures are shown. Note the lack of differences among the genotypes.
FIG. 9. PMA-induced morphological alteration of blood vessels requires RasGRP3 function. Day 5 to 8 ES cell cultures were treated with
PMA, fixed on day 8, and reacted with anti-PECAM antibody. (A to C) Untreated; (D to F) 100 nM PMA. Rasgrp3/ (A and D), Rasgrp3/gt (B
and E), Rasgrp3gt/gt (C and F), and flt-1/ (G) cultures are shown. Note the formation of PECAM-positive endothelial sheets in the PMA-treated
Rasgrp3/ cultures and the intermediate structures in Rasgrp3/gt cultures. Cultures lacking flt-1 also formed endothelial sheets.
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tion phenotype (3). One prominent RasGEF that is expressed
ubiquitously is the mammalian Son-of-Sevenless (SOS) homo-
logue (20). This GEF is complexed with the adaptor protein
Grb2, and the SOS-Grb2 complex translocates to the plasma
membrane via Grb2 association with the cytoplasmic domain
of activated receptor tyrosine kinases, thus promoting SOS
activation of Ras. Studies with B cells suggest that SOS and
RasGRP3 may activate Ras coordinately (53); therefore, SOS
may be able to partially compensate for the lack of RasGRP3
activity in endothelial cells (Fig. 11). Ras activation can also
occur independently of RasGEFs. Protein kinase C (PKC)
activation of extracellular signal-regulated kinases 1 and 2 in
endothelial cells is insensitive to Ras-N17, a dominant negative
form of Ras that sequesters and inactivates RasGEFs (18, 66,
70). In this case, PKC is thought to activate sphingosine kinase
(SPK), and SPK may activate Ras by RasGAP inhibition (Fig.
11). However, PKC also phosphorylates RasGRP3, and this
phosphorylation event is highly correlated with membrane lo-
calization of RasGRP3 and Ras activation in B cells (8, 71).
This finding suggests that PKC may affect cellular functions at
least in part via activation of RasGRP3.
We thus asked whether a gain-of-function manipulation of
RasGRP3 produced a vascular phenotype. Other GEFs up-
regulate their target pathways when they are constitutively
FIG. 10. RasGRP3 is upregulated in flt-1/blood vessels. (A) Northern blot analysis was performed on RNA isolated from flt-1/ cultures
(lane 3). RNA was also isolated from Rasgrp3/ and Rasgrp3gt/gt cultures treated with PMA (lanes 2 and 5) or left untreated (lanes 1 and 4). The
blot was probed for RasGRP3 and then reprobed for the vascular marker PECAM. (B) Graph showing relative levels of RasGRP3 RNA in ES
cell cultures. RasGRP3 RNA levels were normalized to the amount of PECAM RNA.
FIG. 11. Model of Ras activation downstream of VEGF signaling. Several potential pathways downstream of VEGF receptor activation may
lead to Ras activation, and some involve RasGRP3, as follows. (i) Activation of PLC- leads to DAG production and RasGRP3 activation. (ii)
DAG also recruits PKC which can phosphorylate RasGRP3. (iii) PKC may also activate Ras through SPK. (iv) VEGF signaling through SOS/Grb2
may lead to Ras activation. (v) DAG production can occur independently of VEGF signaling through aberrant glucose metabolism.
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localized to the membrane, so developing ES cell-derived ves-
sels were incubated with PMA, a phorbol ester that mimics
DAG and is predicted to localize RasGRP3 to the membrane
(47). RasGRP3-expressing wild-type vessels responded dra-
matically to PMA, exhibiting extensive morphogenetic changes
that resulted in the formation of sheets rather than branched
vessels. A preliminary analysis indicates that both increased
endothelial proliferation and aberrant cell-cell interactions
contribute to the phenotypic response to PMA (Roberts and
Bautch, unpublished). PMA has complex effects on endothelial
cells, since it also potently activates PKC and increases vascu-
lar permeability (39, 52, 75). However, despite the potential
complexity of the endothelial response to PMA, it is dependent
on RasGRP3, since Rasgrp3gt/gt vessels were completely refrac-
tory to the PMA-induced morphogenetic changes. This result
shows that RasGRP3 functions in endothelial cells and con-
firms that the Rasgrp3gt allele is a loss-of-function mutation.
Future work will delineate the components downstream of the
response of newly formed vessels to PMA and how these com-
ponents interact with RasGRP3.
How does RasGRP3 function in endothelial cells? One clue
comes from the phenotype of wild-type vessels incubated with
PMA, which in many aspects resembles the phenotype of ves-
sels with up-regulated VEGF signaling. Although the VEGF
receptor flt-1 (VEGFR-1) can activate downstream signaling
pathways in some contexts (82), flt-1 is thought to act devel-
opmentally primarily as a decoy receptor to bind excess VEGF
(42, 44, 59). Thus, deletion of flt-1 in ES cell cultures leads to
aberrant vascular morphogenesis and large endothelial sheets,
and these perturbations are consistent with up-regulation of
VEGF signaling (42). This phenotype results from both in-
creased proliferation and compromised migration of affected
endothelial cells (42, 44). RasGRP3 expression is up-regulated
in the flt-1 mutant ES cell cultures, consistent with the possi-
bility that excess Ras activation through RasGRP3 contributes
to the flt-1 mutant phenotype. In addition, data suggests that
RasGRP3 also activates other Ras-related GTPases such as
Rap (55, 68, 78), so RasGRP3-mediated activation of Rap may
also contribute to the vascular phenotype seen in the flt-1
mutants and upon exposure to PMA. However, since PMA
stimulation of primary endothelial cells results in robust Ras
activation (75), Ras signaling is likely to contribute extensively
to PMA-mediated vascular effects. Moreover, preliminary re-
sults indicate that the farnesyltransferase inhibitor FTI-2153
partially rescues the aberrant vascular phenotype induced by
PMA (Roberts and Bautch, unpublished), a finding consistent
with a model in which Ras is a downstream target of Ras-
GRP3. Whether PMA stimulation also activates Rap in endo-
thelial cells is yet to be determined. It will be interesting to
determine which pathways are activated downstream of the
flt-1 mutation, and which components of VEGF signaling are
mediated by Ras activation in vivo.
Our data demonstrate that endothelial cell expression of a
GEF, RasGRP3, is downstream of VEGF signaling during
blood vessel formation in vivo. RasGRP3 functions in endo-
thelial cells, as it is required for PMA-induced vascular mor-
phogenetic defects, but it does not appear to be essential for
vascular development or normal angiogenesis. We suggest that
this mode of Ras activation downstream of VEGF signaling is
important in situations of pathway activation where redundant
pathways are not up-regulated. RasGRPs uniquely utilize
DAG to localize to the membrane and activate Ras, and DAG
is produced by several intracellular pathways. Thus, disease
states that lead to excess DAG production may depend on
RasGRP3-mediated Ras activation (Fig. 11). Several studies
have correlated aberrant glucose metabolism and concomitant
increases in DAG with diabetes (for reviews, see references 10
and 77). Thus, RasGRP3 may be involved in the vascular
complications of diabetic patients, such as nephropathy and
retinopathy, and it may provide a novel target for therapeutics
aimed at ameliorating diabetic symptoms.
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